

**Expression Of Major Intracellular Components of the NF- κ B
Alternative Pathway (NF- κ B2, RelB, NIK and Bcl3) is Associated
With Clinical Outcome of NSCLC Patients**

^{1§}Foteinos-Ioannis D. Dimitrakopoulos, ^{1§}Anna G. Antonacopoulou, ^{1§}Anastasia E. Kottorou, ²Nikolaos Panagopoulos, ¹Fotini Kalofonou, ³Fotios Sampsonas, ⁴Chrisoula Scopa, ⁵Melpomeni Kalofonou, ¹Angelos Koutras, ¹Thomas Makatsoris, ²Dimitrios Dougenis, ⁶Helen Papadaki, ⁷Malcolm Brock, ^{1*}Haralabos P. Kalofonos

¹Molecular Oncology Laboratory, Division of Oncology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece.

²Department of Cardiothoracic Surgery, Medical School, University of Patras, Patras, Greece.

³Department of Respiratory Medicine, University Hospital of Patras, Patras, Greece.

⁴Department of Pathology, Medical School, University of Patras, Patras, Greece.

⁵Institute of Biomedical Engineering, Imperial College London, London, United Kingdom.

⁶Department of Anatomy, Medical School, University of Patras, Patras, Greece.

⁷Division of Thoracic Surgery, Department of Surgery, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.

§ These authors contributed equally to this work.

*Corresponding author: Prof. Haralabos P. Kalofonos, Division of Oncology, Department of Internal Medicine, Medical School, University of Patras, Rion-Patras 26504, Greece. Tel.: +30 2610999535, Fax: +30 2610994645, E-mail: kalofonos@upatras.gr

Clinicopathological characteristics	Cases <i>n</i> (%)
Total	151 (100)
Age (years) Median (range)	66 (40-84)
Gender	
Total	151 (100)
Male	139 (92.1)
Female	12 (7.9)
Smoking (pack-years)	
Total	151 (100)
Cases (%)	59 (39.1)
Mean (range)	87.63 (20-165)
NA	92 (60.9)
Primary location	
Total	151 (100)
Left lung	66 (43.7)
Right lung	85 (56.3)
NA	-
Histology	
Total	151 (100)
Squamous	86 (57.0)
Adenocarcinoma	54 (35.8)
Large carcinoma	10 (6.6)
NA	1 (0.6)
Stage	
Total	151 (100)
I	59 (39.1)
II	44 (29.1)
III	45 (29.8)
IV	2 (1.3)
NA	1 (0.7)
Grade	

Total	151 (100)
I	4 (2.6)
II	70 (46.4)
III	67 (44.4)
NA	10 (6.6)
Maximum diameter (cm)	
Total	151 (100)
Cases (%)	147 (97.4)
Mean (range)	5.09 (0.70-21.00)
NA	4 (2.6)
Lymph node infiltration	
Total	151 (100)
No	79 (52.3)
Yes	65 (43.0)
NA	7 (4.6)
Metastasis (adrenals)*	
Total	151 (100)
No	29 (19.2)
Yes	7 (4.6)
NA	115 (76.2)
Metastasis (liver)*	
Total	151 (100)
No	30 (19.9)
Yes	5 (3.3)
NA	116 (76.8)
Metastasis (brain)*	
Total	151 (100)
No	30 (19.70)
Yes	9 (6.0)
NA	112 (74.2)
Metastasis (bone)*	
Total	151 (100)
No	23 (15.2)

Yes	17 (11.3)
NA	111 (73.5)
Metastasis (adrenals-liver-brain-bone)*	
Total	151 (100)
No	9 (6.0)
Yes	36 (23.8)
NA	106 (70.2)
Survival (2 years)	
Total	151 (100)
Dead	56 (37.1)
Alive	93 (61.6)
NA	2 (1.3)
Survival (3 years)	
Total	151 (100)
Dead	75 (49.7)
Alive	71 (47.0)
NA	5 (3.3)
Survival (5 years)	
Total	151 (100)
Dead	91 (60.3)
Alive	55 (36.4)
NA	5 (3.3)
Relapse	
Total	151 (100)
No	14 (9.3)
Yes	23 (15.2)
NA	114 (75.5)

Supplementary Table S1. Clinicopathological characteristics and survival data of NSCLC patients. Abbreviations: NA, data not available or unknown. * Metastasis status refers to metastases, which were developed the patients during the observation period.